Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-high-Risk Neuroblastoma: A Groupwide Historically Controlled Phase III Study

Recruiting
1 years or below
All
Phase N/A
1 Location

Brief description of study

This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma.

Detailed description of study

This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma.

Participants will not be paid for their participation.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Non-high-Risk Neuroblastoma,neuroblastoma,cancer,oncology,pediatric,infant,kid,kids,child,children,baby,riley
  • Age: 1 years or below
  • Gender: All

Inclusion Criteria
12 months of age at diagnosis with INRG stage L1 or stage M neuroblastoma or nrollment on ANBLOOB1 is required for all newly diagnosed patients
Must have newly diagnosed v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN) non-amplified neuroblastoma or MYCN non-amplified ganglioneuroblastoma verified by histology
Exclusion Criteria
Patients with MYCN amplified tumors

Updated on 04 Aug 2024. Study ID: 1410350695 (PHO-COG-FALLON-ANBL1232)

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Zip Code
Please provide your 5-digit zip code
0 0 /250
Other language

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team